Trial Profile
A Double Blind Randomized Trial of Cediranib versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Aug 2023
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 17 Dec 2013 Results published in the European Journal of Cancer.
- 31 Oct 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 20 Jun 2013 Planned end date changed from 1 Dec 2012 to 1 Sep 2013 as reported by ClinicalTrials.gov.